141 related articles for article (PubMed ID: 24400239)
21. Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil.
Tanuma Y; Tanaka Y; Okamoto T
Urol Ann; 2021; 13(3):296-300. PubMed ID: 34421268
[TBL] [Abstract][Full Text] [Related]
22. Randomised Clinical Trial of Prostatic Artery Embolisation Versus a Sham Procedure for Benign Prostatic Hyperplasia.
Pisco JM; Bilhim T; Costa NV; Torres D; Pisco J; Pinheiro LC; Oliveira AG
Eur Urol; 2020 Mar; 77(3):354-362. PubMed ID: 31831295
[TBL] [Abstract][Full Text] [Related]
23. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials.
Vlachopoulos C; Oelke M; Maggi M; Mulhall JP; Rosenberg MT; Brock GB; Esler A; Büttner H
Int J Clin Pract; 2015 Dec; 69(12):1496-507. PubMed ID: 26299520
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
[TBL] [Abstract][Full Text] [Related]
25. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
Tanuma Y; Tanaka Y; Takeyama K; Okamoto T
Urol Ann; 2016; 8(1):20-5. PubMed ID: 26834396
[TBL] [Abstract][Full Text] [Related]
26. Correlations among Lower Urinary Tract Symptoms, Bother, and Quality of Life in Patients with Benign Prostatic Hyperplasia and Associated Fluctuations with Tamsulosin Administration.
Gotoh M; Matsukawa Y; Funahashi Y; Kato M; Maseki Y; Narita H; Kamihira O; Hattori R
Low Urin Tract Symptoms; 2012 Jan; 4(1):45-50. PubMed ID: 26676459
[TBL] [Abstract][Full Text] [Related]
27. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
[TBL] [Abstract][Full Text] [Related]
28. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia.
Jhang JF; Liao CH; Kuo HC
Int J Clin Pract; 2014 Jun; 68(6):743-8. PubMed ID: 24471413
[TBL] [Abstract][Full Text] [Related]
29. Naftopidil for the treatment of benign prostate hyperplasia: a systematic review.
Castiglione F; Benigni F; Briganti A; Salonia A; Villa L; Nini A; Di Trapani E; Capitanio U; Hedlund P; Montorsi F
Curr Med Res Opin; 2014 Apr; 30(4):719-32. PubMed ID: 24188134
[TBL] [Abstract][Full Text] [Related]
30. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
31. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
[TBL] [Abstract][Full Text] [Related]
32. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
Shalekenov BU; Kuandykov YA; Shalekenov SB
Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.
Bae JH; Kim SO; Yoo ES; Moon KH; Kyung YS; Kim HJ
Korean J Urol; 2011 Apr; 52(4):274-8. PubMed ID: 21556215
[TBL] [Abstract][Full Text] [Related]
34. Symptoms Predictive for Efficacy of Naftopidil in Patients with Benign Prostate Hyperplasia.
Funahashi Y; Hattori R; Yoshino Y; Matsukawa Y; Sassa N; Gotoh M
Low Urin Tract Symptoms; 2011 Sep; 3(2):113-7. PubMed ID: 26676397
[TBL] [Abstract][Full Text] [Related]
35. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Rademaker A; Lloyd GL; Gann P
J Urol; 2005 Oct; 174(4 Pt 1):1327-433. PubMed ID: 16145413
[TBL] [Abstract][Full Text] [Related]
36. Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Lyauk YK; Jonker DM; Lund TM; Hooker AC; Karlsson MO
AAPS J; 2020 Aug; 22(5):115. PubMed ID: 32856168
[TBL] [Abstract][Full Text] [Related]
37. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.
Wang LW; Li JL; Yu Y; Xiao RH; Huang HW; Kuang RR; Hai B
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):531-535. PubMed ID: 28786061
[TBL] [Abstract][Full Text] [Related]
38. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
39. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.
Masumori N
Ther Clin Risk Manag; 2011; 7():227-38. PubMed ID: 21753885
[TBL] [Abstract][Full Text] [Related]
40. Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α
Kobayashi M; Nukui A; Kamai T
Int Neurourol J; 2017 Sep; 21(3):197-203. PubMed ID: 28954461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
